trending Market Intelligence /marketintelligence/en/news-insights/trending/UysJwtQS9NOM5KeC_dJ0Ew2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lundbeck Q2 profit up; FY guidance raised on one-time gain

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lundbeck Q2 profit up; FY guidance raised on one-time gain

H. Lundbeck A/S booked 1.29 billion Danish kroner, or 4.12 kroner per share, in core profit from operations, or core EBIT, for the second quarter ended June 30.

The result compares to the second-quarter 2016 core EBIT of 726 million kroner, or 2.26 kroner per share, and the S&P Capital IQ normalized EPS consensus estimate of 3.52 kroner.

Core results exclude the impact of certain items. Accounting for those, the company booked 1.05 billion kroner, or 3.08 kroner per share, in second quarter profit from operations, or EBIT, which compares to 469 million kroner, or 1.18 kroner per share, in the same period of 2016.

The Danish pharmaceutical company generated 4.28 billion kroner in second-quarter revenues, up from 3.75 billion kroner in the same quarter of 2016. The company's sales were helped by its anti-depressants Brintellix/Trintellix and Rexulti.

Research and development costs for the quarter fell 7% year over year to 622 million kroner due to fewer ongoing late-stage trials.

The Danish pharmaceutical company is now targeting 4.1 billion kroner to 4.5 billion kroner in 2017 profit from operations, or EBIT, as opposed to 3.6 billion kroner to 4 billion kroner previously.

Full-year revenue guidance has been increased to between 16.7 billion kroner and 17.5 billion kroner from 16.5 billion kroner and 17.3 billion kroner previously.

The forecast includes a gain of 200 million kroner on the sale of the company's two buildings in Copenhagen, Denmark.

As of Aug. 8, US$1 was equivalent to 6.34 Danish kroner.